Delphine Launay
Geneve, GE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans.
Journal: Antimicrobial agents and chemotherapy
Published: September 22, 2025
Safety, tolerability and pharmacokinetics of DNDI-6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants.
Journal: British journal of clinical pharmacology
Published: April 04, 2025
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility.
Journal: ACS medicinal chemistry letters
Published: December 12, 2020
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
Journal: European journal of medicinal chemistry
Published: July 15, 2020
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
Journal: Journal of medicinal chemistry
Published: February 21, 2018
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.
Journal: Bioorganic & medicinal chemistry letters
Published: August 23, 2017
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.
Journal: Journal of medicinal chemistry
Published: May 02, 2017
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
Journal: Bioorganic & medicinal chemistry letters
Published: February 14, 2017
Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis.
Journal: Organic process research & development
Published: October 05, 2016
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.
Journal: Journal of medicinal chemistry
Published: February 23, 2016
Aminothiazoles: Hit to lead development to identify antileishmanial agents.
Journal: European journal of medicinal chemistry
Published: June 25, 2015
Last Updated: 09/26/2026